InvestorsHub Logo
Followers 39
Posts 1454
Boards Moderated 0
Alias Born 06/14/2011

Re: None

Thursday, 01/12/2017 7:14:36 PM

Thursday, January 12, 2017 7:14:36 PM

Post# of 10796
COV.V - Case for double in 2017...

...is very well laid out. Not a zip code changer in 1 year, but thought I would post here anyways.

Covalon came out with this PR about a week ago which suggests that Q1 of 2017 should generate positive EBITDA, and earnings (net income) which should put COV.V on Canadian smallcap fund managers radar:

http://ir.covalon.com/phoenix.zhtml?c=183092&p=irol-newsArticle&ID=2233328

I found this post below which confirmed what I saw in my DD (65-70% gross margins). This investor has been following Covalon longer than me. I started tracking once a few people picked Covalon for either the last or second last SKILLZ Pick 3 contest.



He is expecting $CAD 6.5M in total opex in F2017. Total opex for F2016 is tracking towards $CAD 6.1M (4.6/75%)



Covalon could technically come down to the $1.90 level but the analysis above is quick to do any I am sure many other investors are thinking the same so I put in my order at 2.15 today which was filled. Pretty thinly traded too.



Note to get to the $CAD 0.30 in earnings the investor divided $6.5M by (14.422M shares o/s @ June 30 + 5.793M warrants = $20.2M FD shares) = $0.32 in earnings. The 14.422 includes shares issued up to June 30 for conversion of convertible debt. Covalon is now det free with $CAD 3.1M of working capital at June 30.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.